Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GTX-102 Oral Spray vs Betamethasone in Healthy Subjects
NCT05531890Phase 1Unknown
- Sponsor
- Grace Therapeutics, Inc.
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apazunersen in ataxia-telangiectasia (AT) (6 arms), sponsored by Grace Therapeutics, Inc. Primary endpoints: AUC from 0 to 72 hours post-dose, AUC from time 0 to infinity and 1 more. Status: unknown.
02
Drugs
apazunersen
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT05531890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531890.